Clovis, with new study data, hopes to be first to develop a PARP for prostate cancer

Clovis, with new study data, hopes to be first to develop a PARP for prostate cancer

STAT Plus: Clovis, with new study data, hopes to be first to develop a PARP for prostate cancer

By ADAM FEUERSTEIN

ANNIE CAVANAGH/WELLCOME COLLECTION

Clovis Oncology disclosed new clinical trial results showing a 44 percent tumor response rate following treatment with its PARP inhibitor.

READ MORE